In the latest quarter, NovaBay Pharmaceuticals executed a fundamental strategic pivot, legally changing its name to Stablecoin Development Corporation and transitioning towards a blockchain-centric business model. It now holds approximately 2.15 billion SKY tokens engaged in on-chain staking activities, generating staking rewards that represent the company’s new revenue stream. This move away from pharmaceuticals positions it within the emerging digital asset ecosystem but accompanies notable financial reporting complexities and regulatory risks. Key growth drivers include management alignment via new equity incentives and expanding token holdings, while close monitoring of accounting restatements and market dynamics remains essential.